JenaValve Technology has received premarket approval from the FDA for its Trilogy THV System.
The system is now the first transcatheter device in the U.S. with a dedicated indication for patients with symptomatic, severe aortic regurgitation, according to a March 18 news release from the company.
The FDA approval is supported by a study that displays successful results with the Trilogy THV System. JenaValve will launch activity with the system with clinical study sites and new hospitals.
There are tens of thousands of individuals in the U.S. each year who are identified as having symptomatic, severe AR, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
